Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies (NCT02666248) | University of Pennsylvania | 2016-05-23 |
Track Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion automatically
Every clearance here is in the API, with alerts when new ones post.